Third, we systematically tested multiple machine learning approaches (each with strengths and weaknesses) that consistently confirmed the added utility of serum multi-protein biomarker profiles as feature input in robustly predicting real-world MS disability beyond the benchmark clinical profile alone or clinical profile plus single protein at a time such as NfL or GFAP. This evidence concerns the gene GFAP and myeloid sarcoma.